Findings include GLP-1R agonists and pioglitazone use, with drop in hospital admissions <\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Oct. 8, 2021 (HealthDay News) — Use of glucose-regulating medications may improve outcomes for COVID-19 patients with type 2 diabetes mellitus, according to a study published online Sept. 27 in Diabetes<\/em>.<\/p>\n Jennifer E. Nyland, Ph.D., from Penn State College of Medicine in Hershey, and colleagues used data from the TriNetX COVID-19 Research Network of 56 large health care organizations to assess the relationship between glucose-regulating medications and COVID-19 outcomes.<\/p>\n The researchers found that after matching for age, sex, race, ethnicity, body mass index, and significant comorbidities, use of glucagon-like peptide-1 receptor (GLP-1R) agonists and\/or pioglitazone was associated with significant reductions in hospital admissions (GLP-1R: relative risk [RR], 0.67; pioglitazone: RR, 0.71). There was also an association between use of GLP-1R agonists and reductions in respiratory complications (RR, 0.62) and incidence of mortality (RR, 0.58). Similarly, there was an association observed between use of dipeptidyl peptidase-4 (DPP-4) inhibitors and a reduction in respiratory complications (RR, 0.82). Continued use of DPP-4 inhibitors after hospitalization was associated with a decrease in mortality versus those who discontinued use (RR, 0.45).<\/p>\n “The scientific community continues to search for treatments that may complement vaccination by further reducing the risk of hospitalization, respiratory complications, and death from COVID-19 in at-risk patients with preexisting conditions like diabetes,” Nyland said in a statement.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n